New Zealand expects big savings with generic quetiapine

Home/Policies & Legislation | Posted 17/09/2010 post-comment0 Post your comment

The New Zealand pharmaceutical management agency, PHARMAC, expects to save NZ$24 million (US$17.1 million) over the next five years following price reductions for certain antipsychotic drugs. The agency intends to use the savings to fund other medicines.


PHARMAC’s decision to fund the Dr Reddy’s brand of the antipsychotic medicine quetiapine adds a third option to the existing two brands of quetiapine: Quetapel and Seroquel.

The New Zealand reference pricing system will also cause the reimbursement price of one of the existing drugs on the market, Seroquel, to be reduced. This could cause patient co-payments to increase unless the manufacturer, AstraZeneca, decides to adjust the price.

About 34,000 people a year take quetiapine, which is used to treat schizophrenia and other psychotic illnesses and is occasionally prescribed as a sedative. PHARMAC expects any change in brands for patients taking quetiapine to be manageable.

“The savings are important to help PHARMAC manage overall pharmaceutical spending”, says PHARMAC Medical Director, Dr Peter Moodie.


PHARMAC Media Release. Funding change for mental health medicine to save $24 million. 30 August 2010.

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
Home/Policies & Legislation Posted 05/11/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010